SCEPTER-PARTNERS
10.5.2017 16:01:12 CEST | Business Wire | Press release
The Monaco Investment Corporation (MIC) was announced with the support of HSH Prince Albert II of Monaco to lead a direct investment program focused on acquiring controlling positions in companies around the world. The corporation is managed by Scepter Partners, an investment syndicate and merchant bank founded by financier Rayo Withanage and led by a Steering Committee of industry veterans including Brady Dougan, former CEO of Credit Suisse, William Doyle, former CEO of PotashCorp of Saskatchewan and Bob Diamond, founder and CEO of Atlas Merchant Capital and former CEO of Barclays. The new sovereign direct investment corporation is focused on serving select investors as invited by Scepter and the Principality. The MIC will initially lead an investment program in financial institutions and natural resources with expansion into other sectors as investment capabilities are acquired.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170510005927/en/
HSH Prince Albert II of Monaco commented: “The Monaco Investment Corporation will change the way sovereign wealth and private investors engage with large cap investments globally. The founders of Scepter and I have both reaffirmed our commitment to back this institution and we will proactively use our capital and relationships for its success. We believe in the financial initiatives and strong leadership of Scepter and we are confident that the MIC will grow into an institution for which we can all be very proud.”
Scepter was established by members of Asian & Gulf based ruling families who assembled a standing syndicate of sovereign investors around $14 billion of discretionary assets from Scepter stakeholders. HH Prince Abdul Ali Yil Kabier, a Prince of Brunei and co-founder of Scepter affirmed: “Their Highnesses and I are collectively committed to supporting Monaco becoming a major player in global direct investment and building value for stakeholders through the lens of sustainable development. We have absolute confidence in Scepter’s leadership and support the development vision of HSH Prince Albert II of Monaco.”
Mr. Withanage, executive chairman of Scepter commented, “We are dedicated to thoughtfully building the MIC into a globally orientated corporation that combines world class investors and operators to develop a powerful stable of companies.” The corporation will be a supranational investment vehicle, exclusively open to sovereign and institutional investors. During its inaugural year, however, the corporation may invite select Forbes 500 families who are residents or friends of Monaco. These families are chosen by geography and industry focus as founding investors in the corporation and part owners of the management company. Mr. Mark Thomas, Vice Chairman of The Sovereign Trust, Scepter's largest shareholder added: "The MIC is the first time a sovereign direct investment structure marries significant long term capital with some of the most successful individual investors in the world. The MIC exists to work with one of Monaco’s most compelling assets, its friends and residents."
The MIC shall initially capitalize upon Scepter’s unique confluence of operating expertise in financial services and natural resources. Leadership will focus its energies primarily over the next few months on the MIC’s early investments and also decide the appointment of internal investment managers and financial institutions to serve the corporation. The MIC is positioned to work exclusively with those global financial institutions that have committed to activities in Monaco and to absorb investment managers who wish to move to a permanent capital platform. Scepter is moving its leadership to Monaco, where it is establishing its global headquarters.
For more information, please visit www.scepterpartners.com .
View source version on businesswire.com: http://www.businesswire.com/news/home/20170510005927/en/
Contact:
Hill+Knowlton Strategies
Christopher Winans, 1-212-885-0381
chris.winans@hkstrategies.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom